

1 **Title Page**

2 **Author names**

3 Sahil Chhabda, Sniya Sudhakar, Kshitij Mankad, Mette Jorgensen, Fernando
4 Carceller, Thomas S Jacques, Ashirwad Merve, Miren Aizpurua, Jane Chalker, Elisa
5 Garimberti, Felice D'Arco

6 **Title**

7 Constitutional mismatch repair deficiency (CMMRD) presenting with high-grade glioma,
8 multiple developmental venous anomalies and malformations of cortical development – a
9 multidisciplinary/multicentre approach and neuroimaging clues to clinching the diagnosis.

10 **Author affiliations**

11 Dr Sahil Chhabda. Neuroradiology fellow, Great Ormond Street Hospital for Children NHS
12 Foundation Trust, Great Ormond Street, London, WC1N 3JH

13 Dr Sniya Sudhakar. Consultant neuroradiologist, Great Ormond Street Hospital for Children
14 NHS Foundation Trust, Great Ormond Street, London, WC1N 3JH

15 Dr Kshitij Mankad. Consultant neuroradiologist, Great Ormond Street Hospital for Children
16 NHS Foundation Trust, Great Ormond Street, London, WC1N 3JH

17 Dr Mette Jorgensen. Consultant paediatric oncologist, Great Ormond Street Hospital for
18 Children NHS Foundation Trust, Great Ormond Street, London, WC1N 3JH

19 Dr Fernando Carceller. Consultant paediatric oncologist, The Royal Marsden Hospital.
20 Downs Road. Sutton. SM2 5PT and the Division of Clinical Studies. The Institute of Cancer
21 Research. 15 Cotswold Road. Sutton. SM2 5NG.

22 Professor Thomas S Jacques. Professor of Paediatric Neuropathology, UCL GOS Institute of
23 Child Health. 30 Guilford Street. London. WC1N 1EH and the Department of
24 Histopathology, Great Ormond Street Hospital for Children NHS Foundation Trust, Great
25 Ormond Street, London, WC1N 3JH

26 Dr Ashirwad Merve. Consultant neuropathologist, Great Ormond Street Hospital for Children
27 NHS Foundation Trust, Great Ormond Street, London, WC1N 3JH

28 Dr Miren Aizpurua. Neuropathology registrar, Great Ormond Street Hospital for Children
29 NHS Foundation Trust, Great Ormond Street, London, WC1N 3JH

30 Dr Jane Chalker. Healthcare Scientist and Head of Molecular Genomics section, SIHMDS-
31 AG Laboratory, London North Genomic Laboratory Hub, Level 2, Camelia Botnar
32 Laboratories, Great Ormond Street Hospital for Children NHS Foundation Trust, Great
33 Ormond Street, London, WC1N 3JH

34 Dr Elisa Garimberti. Healthcare Scientist, SIHMDS-AG Laboratory, London North Genomic
35 Laboratory Hub, Level 2, Camelia Botnar Laboratories, Great Ormond Street Hospital for
36 Children NHS Foundation Trust, Great Ormond Street, London, WC1N 3JH

37 Dr Felice D'Arco. Consultant neuroradiologist, Great Ormond Street Hospital for children.
38 Great Ormond Street. London. WC1N 3JH.

39 **Corresponding author:**

40 Dr Sahil Chhabda. Neuroradiology fellow, Department of neuroradiology. Great Ormond
41 Street Hospital for children. Great Ormond Street. London. WC1N 3JH.

42 e-mail address: schhabda@nhs.net

43 ORCID: 0000-0003-1191-1187

44 **Word Count: 1551 (excluding references and image legends)**

45

46

47

48

49

50

51 **Declarations**

52 **Funding:** All research at GOSH NHS Foundation Trust and UCL Great Ormond Street
53 Institute of Child Health is made possible by the NIHR GOSH Biomedical Research Centre.
54 The views expressed are those of the authors and not necessarily those of the NHS, the NIHR
55 or the Department of Health.

56 TSJ is grateful for funding from the Brain Tumour Charity, Children with Cancer UK, Great
57 Ormond Street Hospital (GOSH) Children’s Charity, Olivia Hodson Cancer Fund, Cancer
58 Research UK and the National Institute of Health Research (NIHR). Our work is supported
59 by the INSTINCT network funded by The Brain Tumour Charity, GOSH Children’s Charity
60 and Children with Cancer UK, and the EVEREST centre funded by The Brain Tumour
61 Charity.

62 FC is partly funded by The Giant Pledge via the Royal Marsden Cancer Charity.

63 **Conflicts of interest/Competing interests:** Not applicable.

64 **Ethics approval:** Not applicable.

65 **Consent to participate:** Not applicable.

66 **Consent for publication:** All authors have consented to this data being used for this
67 publication. Verbal consent has been obtained from the parents of the patient included in the
68 case report for use of clinical information and anonymised imaging.

69 **Availability of data and material:** Not applicable.

70 **Code availability:** Not applicable.

71 **Authors' contributions:** SC – preparation of manuscript and images. SS, KM, MA, AM,
72 TSJ, MJ, FC and FD – review of manuscript.

73

74

75

76 **Abstract:**

77 Constitutional mismatch repair deficiency syndrome (CMMRD) is a rare cancer-
78 predisposition syndrome associated with a high risk of developing a spectrum of
79 malignancies in childhood and adolescence, including brain tumours.

80 In this report we present the case of an 8 year old boy with acute headache, vomiting and an
81 episode of unconsciousness in whom brain imaging revealed a high-grade glioma (HGG).
82 The possibility of an underlying diagnosis of CMMRD was suspected radiologically on the
83 basis of additional neuroimaging findings, specifically the presence of multiple supratentorial
84 and infratentorial developmental venous anomalies (DVAs) and malformations of cortical
85 development (MCD), namely heterotopic grey matter.

86 The tumour was debulked and confirmed to be a HGG on histopathology. The suspected
87 diagnosis of CMMRD was confirmed on immunohistochemistry and genetic testing which
88 revealed mutations in *PMS2* and *MSH6*.

89 The combination of a HGG, multiple DVAs and MCD in a paediatric or young adult patient
90 should prompt the neuroradiologist to suggest an underlying diagnosis of CMMRD. A
91 diagnosis of CMMRD has important treatment and surveillance implications not only for the
92 child, but also the family in terms of genetic counselling.

93 **Keywords:**

94 Constitutional mismatch repair deficiency syndrome, CMMRD, high-grade glioma,
95 developmental venous anomaly, grey matter heterotopia, malformation of cortical
96 development

97 **Abbreviations:**

98 ACC = Agenesis of the corpus callosum; CM = Cavernous malformation; CMMRD
99 = Constitutional mismatch repair deficiency syndrome; CNS = Central nervous system;
100 DVA = Developmental venous anomaly; EEG = electroencephalography; HGG = High-grade
101 glioma; IDH1 = Isocitrate dehydrogenase 1; MCD = malformation of cortical development

102

103

104 **Introduction**

105 Constitutional mismatch repair deficiency syndrome (CMMRD, OMIM: 276300 and
106 ORPHA: 252202) is a rare cancer-predisposition syndrome which occurs as a result of
107 biallelic germline mutations in the *MLH1*, *PMS2*, *MSH2* or *MSH6* mismatch repair genes.
108 Other names for this entity are brain tumour predisposition syndrome type 1 (BTPS1),
109 mismatch repair cancer syndrome (MMRCS) or biallelic mismatch repair deficiency
110 (BMMRD) (Kim et al. 2020; Abedalthagafi 2018)

111 It is associated with malignant central nervous system (CNS) tumours in childhood and
112 adolescence. (Kim et al. 2020) Other malignancies associated with CMMRD include
113 haematological malignancies, carcinomas of the gastrointestinal tract and genitourinary
114 system and other malignant tumours such as neuroblastoma and rhabdomyosarcoma. A
115 number of non-neoplastic features have also been described in association with CMMRD,
116 some of which are cutaneous and may be apparent on clinical examination such as café au lait
117 spots, areas of skin hypopigmentation, capillary haemangiomas and lupus erythematosus in
118 descending order of frequency. (Wimmer et al. 2014)

119 We present the case of an 8-year-old boy who presented to his local hospital with acute
120 neurological signs and symptoms in whom MRI of the brain showed a supratentorial high-
121 grade glioma (HGG) and other structural abnormalities, namely MCD and DVAs. The
122 possibility of an underlying diagnosis of CMMRD was raised due to the neuroimaging
123 features and cutaneous findings of café au lait spots. The diagnosis was confirmed on genetic
124 testing.

125 We briefly discuss the clinico-radiological-pathological characteristics of this syndrome,
126 focusing on the key imaging features.

127

128

129

130

131

132 **Case Report:**

133 A previously fit and well 8 year old boy with an unremarkable birth history and normal
134 developmental milestones presented to his local hospital with headache and vomiting. He had
135 been diagnosed with dyslexia and had some difficulties at school. Prior to the onset of these
136 symptoms he was noted to have an altered level of consciousness, thought to be attributable
137 to a partial seizure although this was not recorded on video and he did not undergo
138 electroencephalography (EEG) at the time of presentation. No constitutional or visual
139 symptoms were noted. His sister had a diagnosis of scleroderma.

140 He underwent a contrast enhanced MRI scan of the brain which revealed a solid intra-axial
141 mass within the left occipital lobe with strong enhancement and restricted diffusion of the
142 solid components and internal necrotic areas. There was surrounding vasogenic peri-tumoral
143 oedema and associated mass effect on the left lateral ventricle (Image 1). In addition, there
144 was sub-ependymal heterotopic grey matter and dysplastic grey matter extending from the
145 right frontal horn to the overlying cortex. Susceptibility weighted sequences demonstrated
146 numerous supratentorial and a large infratentorial developmental venous anomaly with a
147 typical 'Medusa head' appearance (Image 2).

148 **Image 1 and legend (please see end of article)**

149 **Image 2 and legend (please see end of article)**

150 He was transferred to our institution for further management. On further clinical examination
151 he was noted to have two café au lait spots on his arm. Maximal safe surgical debulking of
152 the lesion was subsequently performed through a left occipital craniotomy with no
153 complications.

154 The histopathological features of the tumour were those of a HGG, in keeping
155 with glioblastoma, WHO grade IV. *IDH1* mutation was negative. The Ki67 proliferation
156 index was very high. Methylation profiling of the tumour failed. There was
157 immunohistochemical loss of expression of *PMS2* with focal loss of *MSH6* and *MSH2* and
158 relative preservation of *MLH1* expression.

159 The immunohistochemistry findings, in combination with the clinical and radiological
160 findings were highly suggestive of a diagnosis of CMMRD.

161 The diagnosis was confirmed on genetic testing which revealed abnormalities in *PMS2*
162 variant coding 73C>T and variant protein p.(Gln25*) and *MSH6* (NM_000179.2) c.718C>T
163 p.(Arg240*) 43% pathogenic chromatin remodelling/DNA methylation. The family elected
164 not to undergo further genetic testing.

165 **Discussion:**

166 CMMRD is rare, with approximately 200 reported cases in the literature. The most common
167 malignancies associated with CMMRD are haematological malignancies, brain tumours and
168 carcinomas of the gastrointestinal and genitourinary systems. Pre-malignant and non-
169 malignant manifestations are also described and are a part of the diagnostic criteria compiled
170 by the European Consortium 'care for CMMRD' (C4CMMRD). (Wimmer et al. 2014)
171 Phenotypically, the features of CMMRD can overlap with neurofibromatosis type 1, and
172 more recently an overlap with tuberous sclerosis complex has been described. (Shapira
173 Rootman et al. 2020)

174 HGGs account for 26% of all malignancies in patients with CMMRD, usually occurring in
175 the first two decades of life. (Vasen et al. 2014) (Wimmer et al. 2014) In addition to HGGs,
176 low-grade gliomas, medulloblastomas and other embryonal tumours have also been described
177 in association with CMMRD. (Amayiri et al. 2016) (Bakry et al. 2014) (Therkildsen et al.
178 2015)

179 The presence of a HGG at the age of less than 25 years, and the presence of ≥ 2
180 hyperpigmented skin alterations over 1cm score two points each on the diagnostic criteria
181 developed by the C4CMMRD consortium. The total score was therefore four in this case. A
182 total score of 3 or more indicates that testing for CMMRD should be undertaken.

183 There have been case series describing neuroimaging abnormalities in CMMRD in addition
184 to HGG. These include DVAs, grey matter heterotopia and structural abnormalities such as
185 agenesis of the corpus callosum (ACC).

186 DVA is the most common brain vascular malformation in the general population with an
187 incidence of up to 2.6% in autopsy series and 6.4% in imaging series. (Sarwar and
188 McCormick 1978) (Gökçe et al. 2014) DVAs in the brain are usually incidental
189 neuroradiological findings, but may present with symptomatic thrombosis, intracranial

190 haemorrhage and seizures. DVAs have been described in association with other vascular
191 malformations, particularly cavernous malformations (CM). (Ruíz et al. 2009)

192 DVAs have also been described in association with CMMRD. (Shiran et al. 2018) In a recent
193 case series of 10 paediatric patients (age range 1-12 years, mean age 6.5 years) from 3
194 families with confirmed CMMRD undergoing neuroradiological surveillance, multiple DVAs
195 (range 2-7 per patient) were observed in all 10 patients. Three of these patients did not have a
196 CNS tumour, whilst the remainder had either glial tumours (four HGG, one gliomatosis
197 pattern diffuse glioma), medulloblastoma (one patient) and embryonal tumour not otherwise
198 specified (one patient). Non-treatment related CM were also present in two of these patients,
199 one of which was not associated with the DVA. There was no correlation between the
200 location of the tumour and the DVA. (Shiran et al. 2018)

201 Subependymal or periventricular nodular grey matter heterotopia is a MCD which occurs due
202 to abnormal neuronal migration. It is the most common type of heterotopia. (Barkovich and
203 Kuzniecky 2000) It may be an isolated abnormality, or occur in association with other
204 structural brain abnormalities. (Abdel Razek et al. 2009) In a case series of three paediatric
205 patients with a genetic diagnosis of CMMRD, two were noted to have subependymal grey
206 matter heterotopia. Further structural brain abnormalities were also present in these patients
207 including interhemispheric cysts in both patients and ACC in one patient, who subsequently
208 developed a glioblastoma. (Baas et al. 2013)

209 ACC has also been described in association with *PMS2* mutation in two other case reports,
210 one of which also had a concurrent mutation in the *DICER1* gene. (Cheyuo et al.
211 2017)(Gururangan et al. 2008)

212 No further structural brain abnormalities were present in this case. To our knowledge, there
213 are no further published case series or reports describing an association between grey matter
214 heterotopia and CMMRD

215 Whilst the outcomes in CMMRD are poor, there are studies examining the potential for novel
216 treatments such as immune checkpoint inhibition which may have implications for
217 glioblastoma and other hypermutant cancers occurring as a result of CMMRD. (Bouffet et al.
218 2016)

219

220 **Conclusion:**

221 This case adds to the existing literature by demonstrating an association between HGG,
222 multiple DVAs and MCD in a case of genetically confirmed CMMRD in a paediatric patient.
223 To our knowledge, only two cases of CMMRD associated with grey matter heterotopia have
224 been previously described.

225 This constellation of imaging findings in a child, adolescent or young adult, in the appropriate
226 clinical context should prompt the neuroradiologist to raise the possibility of the diagnosis of
227 CMMRD, which can guide further work-up. A correct and timely diagnosis of CMMRD can
228 have implications for treatment, ensuring that the patient is kept under surveillance as per
229 C4CMMRD guidance and also in terms of genetic counselling for the family.

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244 **References:**

- 245 1. Abdel Razek, A.A.K., Kandell, A.Y., Elsorogy, L.G., Elmongy, A. and Basett, A.A.
246 2009. Disorders of cortical formation: MR imaging features. *American Journal of*
247 *Neuroradiology* 30(1), pp. 4–11.
- 248 2. Abedalthagafi, M. 2018. Constitutional mismatch repair-deficiency: current problems
249 and emerging therapeutic strategies. *Oncotarget* 9(83), pp. 35458–35469.
- 250 3. Amayiri, N., Tabori, U., Campbell, B., et al. 2016. High frequency of mismatch repair
251 deficiency among pediatric high grade gliomas in Jordan. *International Journal of*
252 *Cancer* 138(2), pp. 380–385.
- 253 4. Baas, A.F., Gabbett, M., Rimac, M., et al. 2013. Agenesis of the corpus callosum and
254 gray matter heterotopia in three patients with constitutional mismatch repair
255 deficiency syndrome. *European Journal of Human Genetics* 21(1), pp. 55–61.
- 256 5. Bakry, D., Aronson, M., Durno, C., et al. 2014. Genetic and clinical determinants of
257 constitutional mismatch repair deficiency syndrome: report from the constitutional
258 mismatch repair deficiency consortium. *European Journal of Cancer* 50(5), pp. 987–
259 996.
- 260 6. Barkovich, A.J. and Kuzniecky, R.I. 2000. Gray matter heterotopia. *Neurology*
261 55(11), pp. 1603–1608.
- 262 7. Bouffet, E., Larouche, V., Campbell, B.B., et al. 2016. Immune checkpoint inhibition
263 for hypermutant glioblastoma multiforme resulting from germline biallelic mismatch
264 repair deficiency. *Journal of Clinical Oncology* 34(19), pp. 2206–2211.
- 265 8. Cheyuo, C., Radwan, W., Ahn, J., Gyure, K., Qaiser R. and Tomboc, P. 2017.
266 Biallelic PMS2 Mutation and Heterozygous DICER1 Mutation Presenting as
267 Constitutional Mismatch Repair Deficiency With Corpus Callosum Agenesis: Case
268 Report and Review of Literature. *Journal of Pediatric Hematology/Oncology* 39(7),
269 pp. e381-e387
- 270 9. Gökçe, E., Acu, B., Beyhan, M., Celikyay, F. and Celikyay, R. 2014. Magnetic
271 resonance imaging findings of developmental venous anomalies. *Clinical*
272 *neuroradiology* 24(2), pp. 135–143.
- 273 10. Guruangan, S., Frankel, W., Broaddus, R., et al. 2008. Multifocal anaplastic
274 astrocytoma in a patient with hereditary colorectal cancer, transcobalamin II
275 deficiency, agenesis of the corpus callosum, mental retardation, and inherited PMS2
276 mutation. *Neuro-oncology* 10(10), pp. 93-97

- 277 11. Kim, B., Tabori, U. and Hawkins, C. 2020. An update on the CNS manifestations of
278 brain tumor polyposis syndromes. *Acta Neuropathologica*.
- 279 12. Ruíz, D.S.M., Yilmaz, H. and Gailloud, P. 2009. Cerebral developmental venous
280 anomalies: current concepts. *Annals of Neurology* 66(3), pp. 271–283.
- 281 13. Sarwar, M. and McCormick, W.F. 1978. Intracerebral venous angioma. Case report
282 and review. *Archives of Neurology* 35(5), pp. 323–325.
- 283 14. Shapira Rootman, M., Goldberg, Y., Cohen, R., et al. 2020. The great mimicker:
284 Phenotypic overlap between constitutional mismatch repair deficiency and Tuberous
285 Sclerosis complex. *Clinical Genetics* 97(2), pp. 296–304.
- 286 15. Shiran, S.I., Ben-Sira, L., Elhasid, R., et al. 2018. Multiple brain developmental
287 venous anomalies as a marker for constitutional mismatch repair deficiency
288 syndrome. *American Journal of Neuroradiology* 39(10), pp. 1943–1946.
- 289 16. Therkildsen, C., Ladelund, S., Rambech, E., Persson, A., Petersen, A. and Nilbert, M.
290 2015. Glioblastomas, astrocytomas and oligodendrogliomas linked to Lynch
291 syndrome. *European Journal of Neurology* 22(4), pp. 717–724.
- 292 17. Vasen, H.F.A., Ghorbanoghli, Z., Bourdeaut, F., et al. 2014. Guidelines for
293 surveillance of individuals with constitutional mismatch repair-deficiency proposed
294 by the European Consortium “Care for CMMR-D” (C4CMMR-D). *Journal of*
295 *Medical Genetics* 51(5), pp. 283–293.
- 296 18. Wimmer, K., Kratz, C.P., Vasen, H.F.A., et al. 2014. Diagnostic criteria for
297 constitutional mismatch repair deficiency syndrome: suggestions of the European
298 consortium “care for CMMRD” (C4CMMRD). *Journal of Medical Genetics* 51(6),
299 pp. 355–365.

300

301


302

303

304

305

306 **Images and legends:**




307

308 **Image 1: Pre-operative MRI.** Top row (A) axial T2-weighted (B) axial T2 FLAIR-weighted
309 and (C) axial apparent diffusion coefficient. Bottom row (D) axial T1-weighted post-contrast
310 (E) coronal T1-weighted post-contrast and (F) axial susceptibility weighted sequences.

311 There is a solid intra-axial mass within the left occipital lobe with strong enhancement of the
312 solid components and internal necrotic areas. The enhancing component of the lesion shows
313 diffusion restriction. There is surrounding vasogenic peri-tumoral oedema and associated
314 mass effect on the left lateral ventricle. The imaging findings are most in keeping with a
315 high-grade glioma.

316



317

318 **Image 2: Additional imaging clues.** Top row (A) axial T2-weighted imaging demonstrating
319 sub-ependymal heterotopic grey matter (B) sagittal T2-weighted and (C) coronal T2-
320 weighted imaging demonstrating dysplastic grey matter extending from the frontal horn to the
321 overlying cortex. Bottom row (D, E and F) axial susceptibility weighted sequences
322 demonstrate numerous supratentorial and a large infratentorial developmental venous
323 anomaly (DVA). The infratentorial DVA has a typical 'Medusa head' appearance. The
324 combination of findings is suggestive of CMMRD.